Speakers

Expand/Collapse

Alexander Stoeck
Principal Scientist
Merck

Day Two

Thursday 25th February, 2021

4:00 pm | Panel Discussion: Mechanisms of Resistance for Combination Therapies

Katie Smith
Research Investigator
Arvinas

Day Two

Thursday 25th February, 2021

12:30 pm | PROTAC® Degraders to Target KRAS G12C and Beyond

Dafna Bar-Sagi
Executive Vice President & Vice Dean for Science, Chief Scientific Officer
NYU Langone School of Medicine

Day One

Wednesday 24th February, 2021

5:00 pm | Exploiting Oncogenic RAS-Dependent Tumour Cell Vulnerabilities to Design New Therapeutics

Darryl McConnell
Senior Vice President & Research Site Head Austria
Boehringer Ingelheim

Darryl McConnell is currently Senior Vice President and Research Site Head at Boehringer-Ingelheim Regional Centre Vienna, Austria. His goal is to discover new chemical therapeutics for cancer’s so-called undruggable targets together with the team at BI.  Darryl’s interests lie in drugging protein-protein interactions, kinases and pushing the frontiers of PROTACs for cancer patients. Fragment screening, protein crystallography, protein NMR, drug resistance, agile methods in drug discovery and natural product inspired medicinal chemistry are some of his areas of scientific interest. Darryl commenced his career with Boehringer-Ingelheim in 2002 as a Research Laboratory Head and is in his current role since 2015. Prior to this Darryl has worked for Intervet in Vienna from 2001, for Biota Holdings Ltd in Melbourne, Australia from 1999 in the area of respiratory viruses and Chiron Technologies in Melbourne from 1997.  Darryl McConnell received his Bachelor of Science with First Class Honours in 1991 with Professor John Elix at the Australian National University in Canberra. He performed his PhD at the University of New South Wales in Sydney with Professor David Black for which he was awarded the Cornforth Medal for the best chemistry PhD thesis in Australia for that year. Following this he performed a 2 year Postdoctoral study at the University of Sydney with Professor Leslie Field in organometallic chemistry.

Day One

Wednesday 24th February, 2021

12:30 pm | Panel Discussion: Precision Medicine – Patient Selection to Ensure Optimal Clinical Translation & Therapeutic Benefit

10:00 am | Which RAS Mutant Will be the Next After KRAS G12C?

Julian Downward
Associate Research Director
Francis Crick Institute

Julian Downward is an Associate Research Director at the Francis Crick Institute. He leads the Oncogene Biology Group, which investigates how cells grow and multiply and how this process can go wrong and lead to cancer. The team’s research is leading us towards future anti-cancer therapies designed to specifically target tumours while leaving healthy cells unharmed. Julian obtained his bachelor's degree in natural sciences from Cambridge University and then completed his PhD in biochemistry in the laboratory of Michael Waterfield at the Imperial Cancer Research Fund laboratories in London. In the early 1980s, Julian’s work uncovered the importance of EGFR in the development of cancer, thanks to its ability to control cell division. The discovery overturned widely held ideas on the causes of cancer and inspired the development of a new genre of targeted cancer therapies, including the breast cancer treatment Herceptin.   Julian began working on the role of Ras proteins in human cancer in Robert Weinberg's laboratory at the Massachusetts Institute of Technology, prior to starting his own lab in London at the Imperial Cancer Research Fund Laboratories, which are now part of the Francis Crick Institute. The lab has provided critical insights into the molecular mechanisms of proteins in the Ras family and their importance in human tumours. Julian is a member of the European Molecular Biology Organisation, a Fellow of the Royal Society, a Fellow of the Academy of Medical Sciences and an Honorary Fellow of the Royal College of Physicians.

Day One

Wednesday 24th February, 2021

4:30 pm | Approaches to Limiting the Development of Tumour Resistance to KRAS G12C Inhibitory Drugs

12:30 pm | Panel Discussion: Precision Medicine – Patient Selection to Ensure Optimal Clinical Translation & Therapeutic Benefit

Caroline Phillips
Head of Oncology
Redx Pharma

Day One

Wednesday 24th February, 2021

12:30 pm | Panel Discussion: Precision Medicine – Patient Selection to Ensure Optimal Clinical Translation & Therapeutic Benefit

Tina Yuan
Principal Scientist II
Novartix

Day Two

Thursday 25th February, 2021

4:00 pm | Panel Discussion: Mechanisms of Resistance for Combination Therapies

Steve Kelsey
President, Research & Development
Revolution Medicines

Steve is currently President of R and D at Revolution Medicines. He trained as an academic hematologic oncologist in London before joining the pharmaceutical industry in 2000. In London, he ran a clinical practice treating patients with leukemias and lymphomas in a research-focused environment and ran a research laboratory doing both basic and translational research. After two years of leading the clinical development of Sutent® for Pharmacia/SUGEN, he joined Genentech where he became vice president of hematology/oncology, playing a significant role in the development of key products such as Perjeta®, Kadcyla® and Erivedge® as well as other molecules in the company’s oncology portfolio. He then led the development of imetelstat, a first-in-class telomerase inhibitor, at Geron where he served as head of research and development and chief medical officer. Following his time at Geron, Steve served as president of Onkaido Therapeutics, a Moderna Venture focusing on discovery and development of mRNA therapeutics for cancer. During his 17 years in the biotechnology industry, Steve has worked with small molecules, antibodies, antibody-drug conjugates, DNA oligonucleotides and mRNA platforms and has driven multiple industry and industry-academia collaborations as part of the mission to provide better drugs for patients with cancer.

Day Two

Thursday 25th February, 2021

4:00 pm | Panel Discussion: Mechanisms of Resistance for Combination Therapies

3:30 pm | Drugging the RAS (ON) Form of Diverse Oncogenic RAS Mutations

Jurgen Moll
Head of Molecular Oncology
Sanofi

Day Two

Thursday 25th February, 2021

4:00 pm | Panel Discussion: Mechanisms of Resistance for Combination Therapies

Anthony Partridge
Senior Principal Scientist
Merck Sharp & Dohme

Day One

Wednesday 24th February, 2021

10:30 am | Exquisitely Specific Anti-KRAS Biodegraders – Informing Cellular Prevalence of Nucleotide-Loaded States

John O’Bryan
Professor
Medical University of South Carolina

Day Two

Thursday 25th February, 2021

1:30 pm | Insights into Novel Vulnerabilities in Oncogenic RAS: Drugging the “Undruggable”

Sharon Campbell
Liebscher Distinguished Professor
University of North Carolina

Day Two

Thursday 25th February, 2021

1:00 pm | RAS G12C Oxidation & Kinetic Characterisation of Inhibitors

Shubham Pant
Associate Professor GI Medical Oncology, Department of Investigational Cancer Therapeutics
MD Anderson Cancer Center

Day One

Wednesday 24th February, 2021

12:30 pm | Panel Discussion: Precision Medicine – Patient Selection to Ensure Optimal Clinical Translation & Therapeutic Benefit

Day Two

Thursday 25th February, 2021

5:00 pm | KRAS inhibitors: The Tip of the Iceberg & Mechanisms of Resistance

Charly Chahwan
Chief Scientific Officer
SyntheX

Day One

Wednesday 24th February, 2021

3:00 pm | Discovery of Novel Methods of Targeting Oncogenic KRAS G12D Signalling

Jeremie Mortier
Scientist
Bayer

Day One

Wednesday 24th February, 2021

11:00 am | Identification of Novel Covalent Allosteric Binding Pocket for KRAS G12C with Computationally Empowered Workflow

Juan Perez
Professor & Scientific Advisor
Allinky Biopharma

Juan Jesus Perez received a B.Sc. and M. Sc. in Chemistry from the University of Barcelona, Spain in 1977 and Ph. D. from the same Institution in 1982 by a thesis on computational chemistry. He carried out postdoctoral stays in the University of Manchester, UK and Max-Plack Institut fur Physik in Garching bei Muchen, Germany during 1983. He later served as visiting Scientist at the IBM Laboratories in Kingston, New York, between 1987 and 1988 and as Senior Researcher in Molecular Research Institute of Palo Alto, California, between 1991 and 1994. Full Professor of Physical Chemistry at the Universitat Politecnica de Catalunya (UPC) since 1999 and CSO at Allinky since 2009. In regard to research activities he is author of more than 180 articles in specialized journals. His research interests focus on design in molecular engineering. Coauthor of four patents and cofounder of Allinky Biopharma, a start-up devoted to the design of allosteric modulators.

Day Two

Thursday 25th February, 2021

10:30 am | Non-Covalent Allosteric Inhibition - Optimising Design of Small Molecule Allosteric Inhibitors of KRAS

Colin Lindsay
Clinical Senior Lecturer, The University of Manchester; Medical Oncology Consultant
The Christie NHS Foundation Trust

Dr. Colin Lindsay is a Clinical Senior Lecturer in medical oncology, dividing his time 50/50 between research and the clinic. Originally he trained at the CRUK Beatson Institute and Cancer Centre in Glasgow, where he completed a PhD studying genetically-modified mouse models of RAS- and RAF-driven melanoma. Following that he shifted focus to lung cancer through involvement with the CRUK Stratified Medicine Programme, as well as a two year ESMO translational fellowship at the Gustave Roussy Institute in Villejuif, France. His main interests are 1) the implementation of effective treatment strategies for cancers driven by the MAPK pathway, and 2) successful and efficient translation of genomic results for optimal clinical gain.

Day Two

Thursday 25th February, 2021

11:00 am | Optimising RAS Inhibitor Translation Towards Clinical Standard of Care

Gopal Sapkota
Program Leader in Protein Phosphorylation
University of Dundee

Day Two

Thursday 25th February, 2021

10:00 am | Efficient & Rapid Degradation of KRAS

Aaron Hobbs
Assistant Professor
Medical University of South Carolina

Day One

Wednesday 24th February, 2021

2:30 pm | Exploiting Atypical KRAS G12R Mutation to Define KRAS Mutation-Specific Signalling & Therapeutic Vulnerabilities

Terry Rabbitts
Professor of Molecular Immunology
Institute of Cancer Research London

Gary Piazza
Professor of Pharmacology, Chief of Drug Discovery Research Centre
University of South Alabama Mitchell Cancer Institute

Day One

Wednesday 24th February, 2021

5:30 pm | Exploring Data from a Novel Pan-RAS Inhibitor Class

Tommy Turbyville
Principal Scientist
Frederick National Laboratory for Cancer Research

Day Two

Thursday 25th February, 2021

2:00 pm | RAS Dynamic Membrane Interactions

Sara Mainardi
Senior Postdoctoral Researcher
Netherlands Cancer Institute

Dr. Sara Mainardi studied Medical Biotechnologies at the University of Rome La Sapienza. Subsequently, she obtained her PhD degree at the Autonoma University of Madrid by working on KRAS mutant Non-Small Cell Lung Cancer under the supervision of prof. Mariano Barbacid (CNIO). Later on, she joined Rene Bernards lab at the Netherlands Cancer Institute of Amsterdam, to continue working on KRAS-driven tumors with a more translational angle. Currently she is a senior postdoc leading a small team of researchers interested in targeting multiple nodes of the MAPK pathway to treat RAS-driven tumors.

Vadim Gaponeko
Professor in the Department of Biochemistry & Molecular Genetics
University of Illinois at Chicago